ArticleFrontiers in pediatrics2026
Prognostic implications of CD123 in pediatric B-cell acute lymphoblastic leukemia: a single-center retrospective analysis.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Acute lymphoblastic leukemia (ALL) is the most common pediatric hematologic malignancy, with the majority of cases being of B-cell origin. While many patients respond favorably to therapy, a subset experiences early relapse or poor outcomes, underscoring the critical need for reliable prognostic biomarkers. This study investigated the significance of CD123 expression in diagnosing the disease, evaluating therapeutic efficacy, and predicting prognosis in pediatric B-cell ALL (B-ALL). Methods: This retrospective study included 305 pediatric patients with B-ALL admitted to our hematology department from January 2016 to December 2021. All patients were treated following the CCCG-ALL-2015 protocol. Based on flow cytometric evaluation, patients with ≥20% or <20% CD123-expressing blasts were stratified into CD123-positive (CD123 Results: CD123 was expressed on the leukemic blasts of 60.3% of patients, exhibiting a strong positive correlation with CD34 expression ( Discussion: CD123 positivity on leukemic blasts correlates with distinct genetic profiles and favorable clinical outcomes in pediatric B-ALL. Ultimately, integrating CD123 status with early treatment response facilitates accurate risk stratification and guides personalized therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.